Resiquimod

DB06530InvestigationalSmall molecule

A substance being studied in the treatment of some types of skin cancer. When put on the skin, resiquimod causes some immune cells to make certain chemicals that may help... It is also being studied to find out if adding it to a tumor vaccine improves the antitumor immune response.

Mechanism: Resiquimod is a Toll-like receptor 7 (TLR7) and TLR8 agonist that is a potent inducer of alpha interferon (IFN-alpha) and other cytokines.
Curator reviewed
Primary indication: Investigated for use/treatment in genital herpes.Curator reviewed
Formula / weight: C₁₇H₂₂N₄O₂ · 314.3822 g/mol (avg)
Code names: R-848

Resolves to

Compound

UNIIV3DMU7PVXFCAS144875-48-9ChEMBLCHEMBL383322ChEBI36706

Structure

InChIKeyBXNMTOQRYBFHNZ-UHFFFAOYSA-NSMILESCCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC(C)(C)O

Targets

Q9NYK1TLR7Q9NR97TLR8

What you can answer from here — as of September 19, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

28Clinical trialsPhase, status and sponsor resolved per trial

15+ReferencesStructured and connected to the statements they support

Which drugs share a target with Resiquimod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account